This medicinal product is subject to additional monitoring. This will allow quick identification of
new safety information. Healthcare professionals are asked to report any suspected adverse reactions.
See section 4.8 for how to report adverse reactions.
1. NAME OF THE MEDICINAL PRODUCT
Striverdi Respimat 2.5 microgram, solution for inhalation
2. QUALITATIVE AND QUANTITATIVE COMPOSITION
The delivered dose is 2.5 microgram Olodaterol (as hydrochloride) per puff.
The delivered dose is the dose which is available for the patient after passing the mouthpiece.
For the full list of excipients, see section 6.1.
4.2 Posology and method of administration
Posology
The medicinal product is intended for inhalation use only. The cartridge can only be inserted and used
in the Respimat inhaler.
Two puffs from the Respimat inhaler comprise one medicinal dose.
Adults
The recommended dose is 5 microgram olodaterol given as two puffs from the Respimat inhaler once
daily, at the same time of the day.
The recommended dose should not be exceeded.
Elderly population
Elderly patients can use Striverdi Respimat at the recommended dose.
Hepatic impairment
Patients with mild and moderate hepatic impairment can use Striverdi Respimat at the recommended
dose.
There are no data available for use of Striverdi Respimat in patients with severe hepatic impairment.
Renal impairment
Renally impaired patients can use Striverdi Respimat at the recommended dose. There is limited
experience with the use of Striverdi Respimat in patients with severe renal impairment.
Paediatric population